Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 201836 fixed-sequence single-dose safety, PK, PD, and absolute bioavailability study in elderly subjects
NL-OMON43334Active, not recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Nov 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of velmupressin in nocturia, sponsored by Ferring Pharmaceuticals. Primary endpoint: Adverse events. Started Nov 2016; status: active, not recruiting.
02
Drugs
velmupressin
03
Conditions
nocturia
Beyond the preview
Go deeper on NL-OMON43334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43334.